First-in-class P-CAB a game-changer in H. pylori eradication
09 Jun 2026
byNatalia Reoutova
Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), produces a sustained gastric acid suppression effect that is both more profound and more rapid than that of proton pump inhibitors (PPIs), making it an essential component of first-line (1L) and second-line (2L) therapy for Helicobacter pylori eradication, according to Professor Takashi Kawai of Tokyo Medical University Hospital, Tokyo, Japan.
